

ASX ANNOUNCEMENT

27 April 2026

Biome Files Patent Application for Next Generation Probiotic Strain BMB18

Key Highlights:

- Patent application filed for Biome's proprietary probiotic strain BMB18
- Comprehensive strain development collaboration with European research partners is ongoing
- Successful in-vitro study has already indicated BMB18 demonstrates differentiated functional characteristics
- Human clinical trial with La Trobe University on BMB18 strain
 - Randomised, double-blind, placebo-controlled trial expected to commence in Q4 FY26
- Patent filing supports Biome's IP development strategy and competitive positioning
- Direct market access through Biome's leading brand Activated Probiotics provides a pathway for future commercialisation of IP-backed innovations
- Platform for expanded intellectual property exploration across strain development pipeline

Microbiome health company Biome Australia Limited (ASX: BIO) ('Biome' or 'the Company') has filed its inaugural patent application for proprietary next generation probiotic strain BMB18, establishing the Company's entry into intellectual property development and innovation-driven growth.

BMB18 represents the first outcome of Biome's strategic initiative to develop next generation probiotic solutions that extend beyond conventional approaches. The Company has invested in comprehensive strain characterisation and development capabilities, establishing a foundation for continued IP exploration across multiple therapeutic applications.



This next generation approach leverages advanced characterisation methodologies and functional validation to identify strains with distinctive profiles suitable for targeted health applications. Pre-clinical study has indicated BMB18's potential therapeutic properties, including immune system modulation, intestinal barrier support, and antioxidant activity.

BMB18 Clinical Trial Progress

Biome's first human clinical trial on its proprietary probiotic strain, BMB18, has received ethics approvals and is expected to commence in partnership with La Trobe University in Q4. The randomised, double-blind, placebo-controlled trial expects to recruit 240 participants with a goal of further strengthening Biome's data set on BMB18.

BMB18 has been registered with the internationally recognised DSMZ strain bank in Germany, for strain identification, reference and patent purposes. The clinical trial project is expected to underpin ongoing innovation and product development in future periods, supporting the Company's broader IP development strategy.

Results from the clinical trial will inform future product development and commercialisation strategies, with data expected to support BMB18's integration into Biome's existing product pipeline and potential standalone applications.


IP Development Strategy

The patent filing initiates Biome's broader intellectual property development journey. The Company is building systematic capabilities in strain identification, characterisation, and validation, creating a platform for ongoing discovery and development across multiple therapeutic areas.

Future development activities will continue exploring novel strain candidates with the goal of building a portfolio of proprietary assets that differentiate Biome's offerings in the practitioner market.

Direct Commercialisation Advantage

Biome's established mass distribution and practitioner trust create a direct pathway to market for future launches of the Company's proprietary innovations, subject to clinical outcomes, regulatory considerations and commercial assessment.



The practitioner-led strategy requires evidence-based solutions which aligns naturally with Biome's science-driven development approach, supporting premium positioning for IP-backed products.

BMB18 is being evaluated for potential inclusion in Biome's existing product development pipeline. The Company will evaluate optimal commercialisation strategies, including standalone products and combination formulations, aligned with practitioner demand and market opportunities.

Biome Australia's Managing Director and Founder, Blair Vega Norfolk, commented:

"Filing our first patent application represents an important strategic milestone for Biome. BMB18's differentiated functional profile, combined with comprehensive safety and characterisation data, positions us to potentially offer health practitioners and our patients innovative probiotic solutions backed by proprietary science."

"The commencement of our BMB18 clinical trial with La Trobe University adds a potential proprietary IP dimension to our growth story. This demonstrates our commitment to building sustainable IP assets while maintaining our focus on practitioner education and clinical efficacy."

"BMB18 is our first step on an IP exploration journey that we believe will fundamentally differentiate our offerings in the practitioner market."

–ENDS–

This announcement has been authorised for release by the Board of Biome Australia Limited.

About Biome Australia Limited

Biome Australia develops, licenses, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines supported by clinical research. Biome aims to improve health



outcomes and quality of life, making products accessible through professional health channels.

Incorporated in Australia in 2018, Biome distributes locally and internationally. In partnership with leading microbiome research organisations, Biome produces unique live biotherapeutic products with innovative delivery technologies improving stability and efficacy for its flagship Activated Probiotics® range.

Supported by randomised double-blind placebo-controlled clinical trials, Activated Probiotics® and Activated Therapeutics® help prevent and support management of various health concerns including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-recommended distribution, Biome educates health professionals on gut microbiota's systemic health effects, providing evidence-based natural medicines for prevalent chronic health concerns.

For more information visit: www.biomeaustralia.com

Investor Relations


Lauren Dwyer - CFO
corporate@biomeaustralia.com

Media enquiries

media@activated.co

Forward Looking Statements

This release may contain forward looking statements, including but not limited to projections, guidance on future revenues, earnings, other potential synergies and estimates and the future performance of Biome (Forward Looking Statements). Forward Looking Statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such Forward Looking Statements and any projections and assumptions on which these Forward Looking Statements are based. Such statements may assume the success of Biome's business strategies. You are cautioned not to place undue reliance on Forward Looking Statements.



The Forward Looking Statements are based on information available to Biome as at the date of this release. Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in this release. Patent applications are subject to examination processes and grant is not guaranteed. Clinical trial results cannot be predicted and may not support commercial development. Except as required by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise.

To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to the fairness, currency, accuracy, reliability or completeness of information in this release or the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in, implied by, the information in this release or any part of it, or that this release contains all material information about Biome or which a prospective investor or purchaser may require in evaluating a possible investment in Biome or acquisition of securities in Biome.

